Neurosterix

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

News

Neurosterix emerges with $63m for neuroscience pipeline

A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schiz

News

Dr Maky Zanganeh, Summit's president and chief executive

FDA won't approve Summit, Akeso's ivonescimab

The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Editor's Picks